Trials / Sponsors / OSI Pharmaceuticals

OSI Pharmaceuticals

Industry · 16 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 Ependymoma	Phase 2	2011-05-23
Terminated	Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma Recurrent or Refractory Pediatric Ependymoma	Phase 2	2010-09-27
Completed	Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer Advanced Pancreatic Cancer	Phase 1	2010-02-03
Completed	A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carc Non-small Cell Lung Cancer	Phase 3	2006-09-01
Completed	Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Posi Carcinoma, Non-Small-Cell Lung	Phase 2	2006-01-01
Completed	A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small NSCLC	Phase 1	2005-11-01
Completed	A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderate Advanced Solid Tumors	Phase 1	2005-08-22
Completed	A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy	Phase 2	2004-08-01
Completed	A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer Locally Advanced or Metastatic Adenoca of the Biliary Tract	Phase 2	2004-08-01
Completed	Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern C Non-Small Cell Lung Cancer	Phase 2	2004-02-01
Completed	Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy	Phase 2	2003-11-05
Completed	Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma	Phase 2	2003-10-01
Completed	Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors Advanced Solid Tumors	Phase 1	2003-06-01
Completed	OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Ca Pancreatic Cancer	Phase 3	2001-11-29
Completed	OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Carcinoma, Non-small-cell Lung	Phase 3	2001-11-01
Completed	Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic P Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific	Phase 1	2001-07-23